Bristol Myers Squibb (NYSE:BMY) has expanded its artificial intelligence collaboration with Nvidia (NASDAQ:NVDA), announcing plans to deploy an Nvidia DGX SuperPOD powered by DGX Vera Rubin NVL72 systems to strengthen its AI infrastructure for drug discovery and development.
The expansion builds on a partnership that began nearly three years ago and is designed to provide significantly greater computing power for AI-driven research. According to Bristol Myers Squibb, the Vera Rubin architecture delivers up to ten times more performance per megawatt than the previous generation, enabling the company to process larger AI workloads without a corresponding increase in energy consumption.
The enhanced computing platform will support research across oncology, hematology, cardiovascular disease, immunology and neuroscience. Bristol Myers Squibb plans to use the system to train foundation models using its proprietary scientific data while also supporting agentic AI workflows, including automated target identification, target validation and its “Predict First” strategy, where AI-generated insights guide experimental design before laboratory testing begins.
“BMS has made a deliberate bet on AI, and we are beginning to see it pay off in our pipeline and operations,” said Greg Meyers, Chief Digital and Technology Officer at Bristol Myers Squibb. “Expanding our compute capabilities with Nvidia gives our researchers and teams across the business the scale they need to keep BMS at the leading edge of what AI can do for drug discovery and development.”
Robert Plenge, Executive Vice President and Chief Research Officer at Bristol Myers Squibb, said the company’s objective is to improve the quality of research decisions rather than simply accelerate development timelines. “The goal isn’t speed for its own sake; it’s raising the probability that each program we advance is the right one,” he said.
As part of the agreement, Bristol Myers Squibb will also gain access to Nvidia’s BioNeMo platform for biological AI and the BioNeMo Agent Toolkit. Rory Kelleher, Senior Director of Business Development, Healthcare and Life Sciences at Nvidia, said the technology will help the company transform its scientific datasets into proprietary intelligence to improve molecule design and hypothesis testing.
The companies did not disclose the financial terms of the agreement.
Bristol Myers Squibb stock price
Nvidia stock price
